An observational study in Motor Neurone Disease (MND) and Health Adult Subjects, sponsored by The Leeds Teaching Hospitals NHS Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by The Leeds Teaching Hospitals NHS Trust · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies in Amyotrophic Lateral Sclerosis with a site in United Kingdom — 15 open to participants now, 22 under way, 6 of them phase 3. Amyotrophic Lateral Sclerosis · United Kingdom.
Among the 70 studies in Amyotrophic Lateral Sclerosis with a site in United Kingdom, this one is the 10th largest by planned enrollment of the 15 observational ones that give a count, is one of 7 that started in 2026, is one of 15 observational ones, reaches primary completion later than 13 of the 21 other live ones, and was the 70th registered.
980 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 279 are open to participants now.
Browse Amyotrophic Lateral Sclerosis studies →15 of the 70 studies in Amyotrophic Lateral Sclerosis with a site in United Kingdom are open now. Recruiting first, the newest first:
Trace Neuroscience, Inc. · Sites in United Kingdom, Germany, Netherlands
Ages 18–75
NHS Greater Glasgow and Clyde · Sites in United Kingdom
Ages 18+
Royal Brompton & Harefield NHS Foundation Trust · Sites in United Kingdom
Ages 18+
Prilenia · Sites in United Kingdom, United States, Belgium and 10 more countries
Ages 18–80
Vector Y Therapeutics · Sites in United Kingdom, United States, Belgium and 1 more country
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 193 Amyotrophic Lateral Sclerosis studies recruiting now, 118 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 55 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 19 · Phase 3 25
First in 2003; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 108 across 265 observational studies indexed under Amyotrophic Lateral Sclerosis.
Median enrollment 227 across the 55 interventional studies, 73 across the 15 observational. Of the 45 that completed or were terminated, 21 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 70 have an industry lead sponsor. The 10 most frequent:
The Leeds Teaching Hospitals NHS Trust is the lead sponsor of 102 studies on the registry; 16 are open to participants now.
The Leeds Teaching Hospitals NHS Trust has 1 study filed under Amyotrophic Lateral Sclerosis — fewer than ten, so there is no comparison to draw.
6 of the studies in Amyotrophic Lateral Sclerosis with a site in United Kingdom that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04856982Phase 3BiogenStudy to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS Symptoms | 2027-08-07 |
| NCT07818772NHS Greater Glasgow and Clyde7T Imaging Pilot-study in Patients With Motor Neuron Disease to Find Non-Invasive Disease Imaging Biomarkers | 2026-11-30 |
| NCT07393932University of SheffieldMND Together: Phase 1 | 2026-12 |
| NCT07943442The Leeds Teaching Hospitals NHS TrustNovel MRI for an Earlier Diagnosis of Motor Neurone Disease | 2027-05-31 |
| NCT07674667Trace Neuroscience, Inc.FUNCtion ALS: Aiming to Restore UNC13A Function in People Living With ALS | 2027-09 |
Add all 6 to your calendar (.ics) → With an account.
Among the 70 studies in Amyotrophic Lateral Sclerosis with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of the study is Can MR Fingerprinting identify quantitative differences in brains of patients with MND and age-matched healthy controls?
The Investigators will recruit consecutive patients with MND, identified via the Leeds MND clinic.
Patients will be provided with a patient information sheet (PIS) when they attend the clinic and will have the opportunity to discuss the study with a clinician and ask questions.
If they are willing and able to provide informed consent at this time, consent will be taken, and the participant will be reassured they may withdraw at any time. If the patient wishes time to consider the study, with their permission, they will be contacted via telephone after 24 hours and asked whether or not they wish to be included, again reassured they may withdraw at any time.
An email inviting individuals aged 18 or over to undergo MR imaging of the brain will be distributed throughout Leeds Teaching Hospitals Trust. Those interested will be asked to send their contact details via e-mail reply to the Department of Neuroradiology.
Potential participants will be contacted by a member of the research team and will be taken through a pre-prepared questionnaire detailing present and past medical history. Individuals that answer negatively for the presence of chronic or current illness, particularly regarding neurological disease or psychiatric conditions and that are free from medication and that satisfy MR safety regulations (i.e. no cardiac pacemakers or metallic implants) will be provided with an MRI appointment. All participants will be sent (via email and at least 24 hours prior to the MRI appointment) a PIS. Informed consent will be obtained on arrival for their MRI appointment by a member of the research team.
A consultant neuroradiologist will review all imaging for both cohorts. Any incidental pathology discovered on the MRI requiring medical review will be recorded as a 'Foreign Films for Opinion' on the the Leeds Teaching Hospitals Trust radiology information system and will be alerted to the volunteers' GP, reflecting pre-existing practice within Leeds Teaching Hospitals Trust for research imaging studies.
The target population will be patients with MND attending the MND clinic, Leeds Teaching Hospitals Trust and healthy volunteers of workers or relatives of workers within Leeds Teaching Hospitals Trust.
Although MND (ALS) can strike at any age, symptoms most commonly develop between the ages of 55 and 75. Men are slightly more likely to develop ALS than women. However, at older ages, men and women are equally likely to be diagnosed with ALS. Whites and non-Hispanics are most likely to develop the disease, but ALS affects people of all races and ethnic backgrounds.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Additional inclusion criteria for MND participants:
Additional inclusion criteria for healthy volunteers:
Exclusion criteria all participants:
to MRI, including:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MND
Radiation: MRI
Healthy volunteers of workers or relatives of workers within Leeds Teaching Hospitals Trust
Radiation: MRI
MRI of the brain including MRF
Quantitative values of brain cortical regions on MRF
Both cohorts will undergo the same MRI protocol comprising routine clinical structural imaging of the brain and MRF; with a scan time of less than 60 minutes. All images from both cohorts will be reviewed by a consultant neuroradiologist. Should there be any unexpected findings, the volunteers' GP will be informed in writing. After the scan, the volunteers from both cohorts will be free to leave, at which point their direct participation in the study will concluded.
Time frame: Scan time of less than 60 minutes
Started Oct 2026 (actual). Primary completion is estimated for May 2027, 7 months after the start.
Of 128 non-industry observational studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 125. This study's planned 7 months is below that.
Counting every sponsor, half of 137 studies reached it within 64 months; a quarter within 29 and three quarters within 114.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Amyotrophic Lateral Sclerosis →
The Leeds Teaching Hospitals NHS Trust →